Publication:
Impact of tocilizumab on clinical outcomes in severe COVID-19 patients and risk of secondary infection: A case-control study

Simple item page
dc.contributor.authorERTÜRK ŞENGEL, BUKET
dc.contributor.authorsSengel, Buket Erturk; Ozel, Serra; Gul, Fethi; Ilgin, Can; Tigen, Elif Tukenmez; Altunal, Luftiye Nilsun; Kabadayi, Feyyaz; Sili, Uluhan; Aydin, Mehtap; Odabasi, Zekaver; Cinel, Ismail; Korten, Volkan
dc.date.accessioned2022-03-14T09:51:34Z
dc.date.available2022-03-14T09:51:34Z
dc.date.issued2021-05-25
dc.description.abstractObjective: This study aimed to identify the effect of tocilizumab (TCZ) on clinical outcomes in severe COVID-19 patients. Material and Methods: We included hospitalized COVID-19 patients with an initial WHO scale >= 4. We matched the patients with baseline characteristics by using propensity scores. Then, we selected patients with C-reactive protein levels above 30 and showing an upward trend. We assessed the effect of TCZ in patients on clinical outcomes by using Mann - Whitney U and Chi-square tests. Results: Of 200 patients who had an initial WHO scale >= 4, 42 (21%) were given it? in addition to standard of care (SOC). Twenty-five patients (50%) needed mechanical ventilation (MV) in the TCZ group, compared with 35 (21%) of 158 patients with SOC (p<0.01). Nineteen (45%) and 37 (23%) patients died in 30 days in these groups, respectively (p <0.01). The secondary infection rate was significantly higher in the TCZ group (p=0.004). However, no difference was observed in all these parameters in the propensity score-matched cohort (14 patients in ICZ and 14 in the SOC group) (p=0.45, 0.45, 1.0 respectively). Conclusions: Tocilizumab does not provide a beneficial effect on MV requirement and mortality in severe COVID-19, and it does not increase the risk of secondary bacterial infection.
dc.identifier.doi10.5472/marumj.942700
dc.identifier.issn1309-9469
dc.identifier.urihttps://hdl.handle.net/11424/243349
dc.identifier.wosWOS:000657549300004
dc.language.isoeng
dc.publisherMARMARA UNIV, FAC MEDICINE
dc.relation.ispartofMARMARA MEDICAL JOURNAL
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectIL-6
dc.subjectSARS-CoV-2
dc.subjectTocilizumab
dc.subjectRHEUMATOID-ARTHRITIS
dc.subjectEFFICACY
dc.titleImpact of tocilizumab on clinical outcomes in severe COVID-19 patients and risk of secondary infection: A case-control study
dc.typearticle
dspace.entity.typePublication
local.avesis.id8bc6e926-6697-4879-b769-d254681ca834
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages8
oaire.citation.endPage119
oaire.citation.issue2
oaire.citation.startPage112
oaire.citation.titleMARMARA MEDICAL JOURNAL
oaire.citation.volume34
relation.isAuthorOfPublication67d5b9df-08b7-4c37-b042-45ea89a4c23d
relation.isAuthorOfPublication.latestForDiscovery67d5b9df-08b7-4c37-b042-45ea89a4c23d

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Erturk Sengel et al. - 2021 - Impact of tocilizumab on clinical outcomes in seve.pdf
Size:
410.34 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs